Monday 29 July 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $EASY.C) (CSE: $PLTH.C) (NYSE: $APHA) (CSE: $HITI.C) (CSE: $SOL.C)
Investor Ideas #Potcasts;
#Cannabis News and #Stocks on the Move (CSE: $EASY.C) (CSE: $PLTH.C) (NYSE: $APHA)
(CSE: $HITI.C) (CSE: $SOL.C)
Delta, Kelowna, BC –July 29, 2019 (Investorideas.com
Newswire) www.Investorideas.com, a global news source covering leading sectors
including marijuana and hemp stocks and its potcast site, www.potcasts.ca
release today’s edition of Investorideas.com
potcastsCM - cannabis news and stocks to watch plus insight from
thought leaders and experts.
Listen to the podcast:
Read this in full at https://www.investorideas.com/news/2019/cannabis-potcasts/07291EASY-PLTH-APHA-HITI-SOL.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com “Potcast”
featuring cannabis news, stocks to watch as well as insights from thought
leaders and experts.
In
today’s podcast we look at a few early announcements.
SpeakEasy Cannabis
Club Ltd. (CSE: EASY) announced that the Company has completed moving its
diverse and massive in scale genetics into its facility in anticipation of
receiving its cultivation licence in the near future. Fulfilling the requirement of having
genetics present in the facility at the time of licensing, SpeakEasy followed
Health Canada's Cannabis Regulations to the letter. In addition to following federally mandated
Cannabis Regulations, SpeakEasy consulted with provincial and municipal
governments, as well, as its local RCMP to ensure proper procedures were
followed, prior to any movement of the genetics being completed.
SpeakEasy
has accumulated an impressive library of unique genetics from sources outside
existing License Holders, that will be used as starting material and are
currently secured within the facility. The current genetics catalogue spans the
full spectrum, providing the ability to produce a wide range of product grown
both indoor and outdoor, as well as, permitting the ability to develop new
strains, unique to SpeakEasy. "We
believe we have one of the largest genetics libraries in the industry, we are
very fortunate to have such incredible partnerships with industry professionals
and genetics experts," said Patrick Geen, Head Grower.
The
company’s outdoor cultivation site stands ready to receive starting material,
upon granting of their initial cultivation license the company plans to
immediately submit their evidence package for their outdoor field to amend
their license to allow for an outdoor cultivation area on their 60 acre field.
"Going
from a cherry orchard, which has laid fallow for years, to a built out outdoor
cultivation area ready for growing cannabis in four and a half months has been
an incredible achievement, I am so proud of everyone in the SpeakEasy family
for their extraordinary efforts and accomplishments," added Bin Huang,
CEO.
SpeakEasy
also announced that it has hired former RCMP officer Grant Bernier. Upon Mr. Bernier's security clearance through
Health Canada, he will assume the position of Chief Security Officer. With his appointment, the Company aims to set
a new standard in compliance within the industry. Grant will have the authority
to preform independent audits within the Company and will have complete
autonomy. We believe once this system is in place it will set the standard for
compliance in the industry. "We have the utmost confidence that our
products will be second to none and we will continue to strive to ensure that
it will remain that way. Additionally,
it's exciting to know our Company from top to bottom, will become the cornerstone
of exemplary industry standards," said Zena Prokosh, SpeakEasy's QAP.
Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF) announced that it has added HaHa Gummies™ and
Dreamland Chocolates™ to its growing in-house brand portfolio.
HaHa
Gummies and Dreamland Chocolates along with Medizin, TRENDI and Leaf & Vine
will be produced in Planet 13's new 15,000 sq. ft. customer-facing production
facility located at the Planet 13 Las Vegas Cannabis Entertainment Complex.
Planet
13 in-house brands currently represent approximately 15% of all products sold
at the SuperStore. With the opening of the new production facility, Planet 13
intends to continue to grow the in-house brand penetration with a long-term,
sustainable target of approximately 50%. Planet 13 also plans to leverage its
current SuperStore supplier relationships to gain rapid access for its in-house
brands, to premium shelf space in third-party Nevada dispensaries.
"Edibles,
especially premium sativa-based edibles, have been very popular with our
tourist customer base," said Larry Scheffler, Co-CEO of Planet 13.
"HaHa Gummies™ and Dreamland Chocolates™ were designed from the ground up
using the customer insights we have generated from the over 400,000 people we
have served at the SuperStore in just eight months. We expect that the
combination of this deep customer connection and an interactive production
experience at the SuperStore will quickly make both brands Nevada favorites.
The
Company's Phase II expansion, which includes; coffee shop, bistro,
customer-facing production facility, and event space, is expected to open by
the end of Q3. Ongoing permitting delays have impacted the construction
schedule. Construction on Phase II is
progressing at a solid pace and will accelerate once the final permits are
issued.
Bob
Groesbeck, Co-CEO of Planet 13, commented, "Despite ongoing permitting
delays our goal is to open Phase II by the end of Q3 and to enter the wholesale
market in Q4 2019."
Aphria Inc. (TSX: APHA) (NYSE: APHA) today announced that its subsidiary Marigold Projects
Jamaica Limited has received a retail Herb House licence from Jamaica's
Cannabis Licensing Authority ("CLA") to open its first store in
Kingston, Jamaica.
Sensi
Medical Cannabis House will be located at the Peter Tosh Square, Unit #51,
(yes, it is there), Pulse Center, 38a Trafalgar Road, overlooking the Peter
Tosh Museum in New Kingston. The Cannabis House will have a smoking lounge for
on-site consumption, high-end accessories for sale, and feature Marigold
proprietary strains of cannabis and brands called Sensi Gold.
"The
approval of Marigold's first Herb House signals an exciting time for Aphria. We
believe that there is tremendous opportunity in Jamaica from a domestic and
international perspective and we look forward to bringing Sensi products to the
market," said Irwin D. Simon. "Receiving this licence is testament to
our team's hard work and dedication in growing our Caribbean and LATAM business
as we provide high-quality cannabis products in regions. Aphria will continue
to execute on our business plan to create long-term value, sales growth, and
profitably in Canada and internationally."
Marigold
Projects, a 49 per cent owned subsidiary of Aphria Inc., holds a Tier 3 licence
to cultivate more than 5-acres of land with cannabis for medical, scientific
and therapeutic purposes. Marigold Projects cultivation farm is fully
operational, and inventory at opening will exceed 2,700 kgs. The company
maintains an additional 20-acres of vacant land in anticipation of expanding
its cultivation operations, as well as a 10-acre farm in St Catherine.
Sensi
Medical Herb House will have its official opening in August 2019. Marigold plans
to open an additional four Cannabis Houses in Portmore, Ocho Rios, Montego Bay,
and Negril, pending CLA licence approval.
High Tide Inc. (CSE:HITI) (OTCQB:HITIF) today announced that its wholly-owned subsidiary, Famous
Brandz Inc., recently signed its 9th license agreement with I.P.L. for access
to various categories of its large Radio Days inventory of original images
featuring historical celebrities, motion pictures, music albums, comics and
other popular culture artwork. The Radio Days License grants Famous Brandz the
right to reproduce and sell smoking accessories, including but not limited to
bongs, containers, grinders, pipes, trays and vaporizers, to specialty retailers
and distributors across North America over a term of 30 months.
Famous
Brandz has begun the process of designing and producing a wide range of smoking
accessories and cannabis lifestyle products featuring classic images of rock
stars, pin-ups, sirens, horror movie characters and more. "Adding the
Radio Days License to our existing stable of celebrity licenses, which include
but are not limited to Snoop Dogg Pounds, Cheech & Chong's Up in Smoke,
Trailer Park Boys, Sublime and Guns N' Roses, only strengthens Famous Brandz'
industry leading position in licensed product manufacturing and wholesale
distribution," said Raj Grover, President and Chief Executive Officer of
High Tide.
"High
Tide continues to grow on all fronts, domestically and abroad, and this new
line of Famous Brandz products will leverage our vertical integration as well
as our understanding of the cannabis customer," added Mr. Grover.
The
Company also recently renewed its license with Da' Grassy High Inc. until the
end of 2021, which grants Famous Brandz the right to manufacture, distribute
and sell products featuring Kevin Smith's well known movie characters Jay &
Silent Bob, Bluntman & Chronic and Buddy Christ. The DGH License is an
important agreement for Famous Brandz as it has enabled the business to develop
highly recognizable products that have been sold successfully on both a
wholesale and retail basis around the world.
Based on the success of its celebrity licenses, High Tide expects to
continue entering into agreements to reproduce popular brands and likenesses in
the future.
SOL Global
Investments Corp. (CSE: SOL) (OTC: SOLCF) announced that it has purchased an
additional 16,766,250 common shares in the capital of HeavenlyRx Ltd. at a
price of $0.40 for an aggregate subscription amount of CAD$23,909,000.
The
subscription is part of a larger private offering by HeavenlyRx of Heavenly
Shares and as a result of this subscription, SOL Global now holds 44.53% of the
issued and outstanding Heavenly Shares and the other shareholders of Heavenly
Rx collectively hold the remaining 55.47%. The Heavenly Shares are subject to
an indefinite hold period under applicable Canadian securities laws.
"HeavenlyRx,
through the expertise of the new management team under Paul Norman and their
stream of acquisitions, is quickly becoming a dominant player in CBD wellness.
This is a team and strategy we want to be part of in a large way. SOL Global's
continued investment in HeavenlyRx has fast-tracked the on-boarding of highly
relevant consumer brands to the company's portfolio ensuring their solid
foundation as a leader in the CBD wellness" said Andy DeFrancesco,
Chairman & Chief Investment Officer of SOL Global.
Heavenly
Rx is a privately-held Hemp and CBD operating company focused on acquiring
significant ownership interests at minimum, and a short-term mandate to gain
absolute control with a 50.1% - 100% ownership, in various industry-leading
THC-free companies in the cannabinoid wellness space.
HeavenlyRx's
focus is on hemp cultivation, processing and the manufacturing of a diverse
range of traditional CBD products including oils, tinctures, balms, and
vape-ready products. Heavenly Rx will also own and operate its own retail locations
along with health & wellness related studios where it will generate a
repetitive captive audience with a desire for Heavenly Rx's products to be part
of its customers' daily routine. It is expected that Heavenly Rx's portfolio
will include several proprietary brands across numerous consumer product group
verticals such as cosmetics and beauty products, bath and body products, and
infused foods.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Friday 26 July 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (NASDAQ: $GWPH) (CSE: $CURA.C) (CSE: $OH.C) (NASDAQ: $OGI) (CSE: $CL.C)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move
(NASDAQ: $GWPH) (CSE: $CURA.C) (CSE: $OH.C) (NASDAQ: $OGI) (CSE: $CL.C)
Delta, Kelowna, BC –July
26, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its
potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/07261GWPH-CURA-OH-OGI-CL.asp
Today’s podcast overview/transcript:
Good afternoon
and welcome to another episode of Investorideas.com “Potcast” featuring
cannabis news, stocks to watch as well as insights from thought leaders and
experts.
In
today’s podcast we look at a few early announcements.
But first, The
Cannabis
Council of Canada responded to the draft regulation by the Quebec
government to ban the sale of certain edible cannabis products and cannabis
extracts:
"Yesterday's decision by the Quebec
government to issue draft regulation with respect to edible cannabis products
and cannabis extracts is extremely disappointing. If implemented, the efforts
of the legal cannabis industry to replace the illicit market and keep cannabis
out of the hands of minors will be severely hindered," said Megan McCrae,
Board Chair, Cannabis Council of Canada.
The proposed regulation would ban the sale
of treat, confectionery, dessert, and chocolate edible products and all
products believed by the Quebec government to have a direct appeal to minors.
In addition, a cannabis extract may not contain any additives or other
substances intended to modify the odor, taste or color. In addition, it
proposes to place a maximum cap of 30% THC on non-edible products, which will
have the effect of curtailing other products – such as vape pens – from
entering the Quebec market. The proposed regulation would also ban cannabis
topicals.
The Cannabis Council of Canada strongly
support the ethos of the proposed regulations, but its current form inhibits
the legal, regulated cannabis industry from producing and selling a diversity
of products in a controlled, responsible manner to Quebec cannabis consumers,
and instead supports the illicit market for these products. The unregulated
production and distribution of cannabis enriches organized crime and puts youth
at risk. According to public opinion research conducted on behalf of the
Cannabis Council of Canada, 64% of Quebecers support the legalization of
cannabis, as well as safe, regulated access to cannabis products.
The Cannabis Council of Canada is the
national voice for Canada's licensed cannabis producers which advocate for
world-leading federal regulation and the safe, responsible production, access
and use of recreational and medical cannabis products.
GW Pharmaceuticals
plc (NASDAQ: GWPH) today announced that the European Medicines Agency’s (EMA)
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive
opinion recommending marketing authorisation of EPIDYOLEX™ (cannabidiol oral
solution) for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome,
in conjunction with clobazam, for patients 2 years of age and older. The
European Commission (EC) is expected to make a final decision on the marketing
authorisation application (MAA) in approximately two months.
“Today’s
positive CHMP opinion for EPIDYOLEX™ marks a major milestone for patients, and
their families, battling to control two of the most severe and life-threatening
forms of childhood onset epilepsy. Cannabidiol oral solution is the first in a
new class of epilepsy medicines and the first plant-derived cannabis-based
medicine to be submitted for European regulatory review, representing a
historic breakthrough,” said Justin Gover, GW’s Chief Executive Officer. “We
are excited by the potential to bring patients and physicians a rigorously
tested and evaluated cannabis-based medicine with a documented safety and
efficacy profile, manufactured to the highest standards and approved by a
medicines regulator.”
“This
is a significant milestone for patients with LGS and Dravet syndrome as there
remains a severe unmet medical need for these rare, lifelong forms of
epilepsy,” said Professor Martin Brodie, President, International Bureau for
Epilepsy. “Today’s positive opinion brings hope to both patients and their
families of a treatment option which has the potential to better control
seizures and notably improve quality of life.”
“In
my clinic, I often see patients with these highly treatment-resistant
epilepsies who have tried and failed existing therapies. These patients and
their families face a long and challenging road and very few achieve adequate
seizure control,” said Dr Antonio Gil-Nagel Rein, Director of the Epilepsy
Programme, Ruber International Hospital, Madrid. “Based on numerous clinical
trials and the scrutiny of the European medicines regulator, this medicine has
the potential to make a real difference to the lives of many patients.”
The
CHMP’s positive opinion is based on results from four randomised, controlled
Phase 3 trials. These studies incorporate data from more than 714 patients with
either LGS or Dravet syndrome, two forms of epilepsy with high morbidity and mortality
rates, which place a significant burden on families and caregivers. Many
patients with LGS or Dravet syndrome have multiple seizures per day, which puts
them at ongoing risk of falls and injury. Despite current anti-epileptic drug
treatment, both of these severe forms of epilepsy remain highly
treatment-resistant.
Curaleaf Holdings,
Inc. (CSE: CURA) (OTCQX: CURLF) responded yesterday to a letter from the U.S. Food and Drug
Administration
("FDA") informing FDA that the Company has addressed the issues that
were raised in the letter regarding its CBD product marketing.
Upon
receiving the letter, Curaleaf Hemp, the Company's hemp-based CBD product line,
immediately began an extensive review of its website and social media platforms
to remove all statements that FDA identified as non-compliant. This includes
removing the Curaleaf Hemp blog, and the third-party links in it, and removing
any statements and social media posts to which FDA had taken exception.
Additionally, Curaleaf Hemp advised FDA that a number of the products mentioned
in the FDA letter had previously been discontinued. Curaleaf Hemp will continue
to work diligently to ensure that the information it provides to consumers on
its website and social media platforms is fully compliant with FDA
requirements.
"Our
industry needs, wants and appreciates the work the FDA is doing to ensure there
is regulation and compliance in the CBD marketplace," said Joseph Lusardi,
CEO of Curaleaf.
"We
care deeply about our customers and making a difference in our industry.
Curaleaf is committed to being an ethical and responsible company and working
with the FDA to be a leader in our industry, setting the standards and
guidelines to best service our customers and the communities we serve."
Organigram Holdings
Inc. (NASDAQ: OGI) (TSX-V: OGI) announced that it has entered into an advance
payment and purchase agreement with 703454 N.B. Inc. (1812 Hemp) under which
the Company will pre-fund hemp purchases to receive access to as much as 60,000
kilograms of dried hemp flower to be harvested in calendar 2019 for extraction
into CBD isolate.
Organigram
is already a party to a purchase agreement entered into in January 2019 with
1812 Hemp, in which Organigram was granted a right of first refusal on 1812
Hemp’s production of certain hemp cultivars.
“Access
to a large, consistent volume of CBD-producing hemp has become increasingly
important as Canadians express their demand for CBD-rich products for use in
both recreational and medical capacities,” said Greg Engel, CEO, Organigram.
“We’ve heard the call for CBD in the market and this agreement positions
Organigram to meet that demand.”
CannaRoyalty Corp.
d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) announced today that it has divested its 5.1% equity
interest in Alternative Medical Enterprises LLC for total consideration of US$6
Million. As Cresco Labs Inc. is
prohibited under state law from acquiring additional positions in the Florida
market, this divestment was a pre-closing condition to the Company's previously
announced plan of arrangement pursuant to which Cresco has agreed to acquire
all of the issued and outstanding shares of Origin House.
"With
one of the final conditions to closing the Arrangement with Cresco now
complete, we look forward to proceeding to drive value for shareholders as a
combined company, upon the expiration of the anti-trust waiting period,"
commented Marc Lustig, Chairman and CEO of Origin House. "The sale of the
remaining AltMed interest marks a significant milestone in the continued
process whereby Origin House has monetized non-core holdings resulting in both
substantial returns for shareholders and additional cash that has fueled the
Company's growth."
The
Company has received approximately US$3 million on close, with the remaining
portion of approximately US$3 million, paid to Origin House in periodic
installments, ending January 2020. Mr. Lustig has agreed with one of the
purchasers that acquired 4.9% of the 5.1% Interest, Zola Global Investors Ltd.,
to personally repurchase a portion of their interest in AltMed under certain
conditions. Zola is an operationally focused family office with deep expertise
in investing across the legal cannabis sector, providing a source of capital
for corporations divesting assets as part of their merger requirements.
Cresco Labs, Inc. (CSE: CL) (OTCQX: CRLBF) announced that it has obtained eligibility with The
Depository Trust Company (DTC) for its common shares listed on the OTCQX.
“Our
shareholders will now be able to electronically transfer shares between
brokerages in the U.S.,” said Charles Bachtell, Co-founder and CEO of Cresco
Labs. “DTC will allow for a more convenient trading experience for current and
future shareholders, something we hope will have a positive impact on the
liquidity and demand of our stock.”
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available
on iTunes, Spotify, Google Play Music,
Stitcher, Spreaker, YouTube via
Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently compensated
for news publication and distribution, social media and marketing, content
creation and more. Disclosure is posted for each compensated news release,
content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Subscribe to:
Posts (Atom)
-
Investorideas.com - Cannabis Stock News: TransCanna (CSE: TCAN) Product Ranks in Leafly's Top Cannabis Strains List
-
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ...